Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
The safety and immunogenicity of REMUNE, an HIV-specific immune based therapy for HIV infection, was evaluated in a cohort of 30 HIV infected subjects in Thailand. This therapy utilizes a gp120 depleted inactivated virus (HZ321), which exhibits a high degree of conservation with the core antigens of both type B' and E strains of HIV, the predominant Thailand isolates. The treatment was well tolerated, with no serious adverse events reported over the course of the 4-month trial. Treatment in which four doses were administered with REMUNE appeared to boost HIV-specific immune responses, with approximately 75% of the treated subjects demonstrating an increase in either the repertoire or the intensity of the serological response to HIV as measured by Western blot. CD4%, viral load, and weight remained stable over the course of the 4-month study relative to baseline values. Viral subtyping of this cohort revealed a predominance of type 'E'. These data suggest that REMUNE is safe and immunogenic in seropositive Thai subjects and supports further study of the therapeutic potential of REMUNE to treat HIV-1 infection.
Limsuwan
A
A
Department of Pathobiology, Mahidol University, Bangkok, Thailand.
Churdboonchart
V
V
Moss
R B
RB
Sirawaraporn
W
W
Sutthent
R
R
Smutharaks
B
B
Glidden
D
D
Trauger
R
R
Theofan
G
G
Carlo
D
D
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D000328:Adult; D000595:Amino Acid Sequence; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization; D008297:Male; D008969:Molecular Sequence Data; D012367:RNA, Viral / Q000097:blood; D013785:Thailand
D016915:AIDS Vaccines; D012367:RNA, Viral; C105086:remune